DOV Pharmaceutical, Inc. is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. The Company has previously funded drug development programs that are now at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (which has completed a pilot Phase 2 clinical trial), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, for bicifadine, with Blue Note Pharmaceuticals, for DOV diltiazem and with Neurocrine Biosciences, or Neurocrine, for indiplon..

DOV 21,947, is a triple reuptake inhibitor (serotonin, norepinephrine and dopamine inhibitor), or TRI, with potential efficacy in the treatment of depression and obesity. DOV 102,677 is another TRI, with potential efficacy in the treatment of alcohol abuse..

The Company’s reuptake inhibitor discovery platforms, including TRIs, norepinephrine and dopamine reuptake inhibitors, serotonin and dopamine reuptake inhibitors, and SNRIs (serotonin and norepinephrine reuptake inhibitors) involve compounds that may be able to treat a wide variety of neuropsychiatric disorders ranging from depression and attention deficit hyperactivity disorder, to pain and obesity. The Company has preclinical molecules belonging to each of these four classes. .

After considering the various options available to the Company in light of the Company’s financial circumstances, its Board of Directors approved a plan to deregister the Company's common stock under the Securities Exchange Act of 1934, as amended. Upon filing of the appropriate form on January 16, 2009, the Company's obligation to file certain reports and forms with the SEC, including Forms 10-K, 10-Q and 8-K, was suspended..

The Company operates on a very limited basis and is focused on soliciting interest in the sale or license of the Company’s business and assets, either as a single entity or in a series of transactions..

DOV Pharmaceutical, Inc. Corporate Communications Department
Phone: 732.907.3600
Email: barbara_duncan@dovpharm.com
Email: pskolnick@dovpharm.com
P. O. Box 1320
Little Falls, NJ 07424